Marty Makary has resigned as commissioner of the Food and Drug Administration (FDA), amid reports of internal conflict regarding the agency’s policies. His exit follows tensions over the FDA’s recent approval of flavored e-cigarettes from Glas Inc., which was reportedly influenced by pressure from President Trump, despite Makary’s reservations. Sources indicate that his departure was linked to this vaping dispute, and there were also indications that Trump had signed off on a plan to remove him. Makary’s resignation is part of a larger shakeup within the Department of Health and Human Services, which oversees the FDA, following the recent departure of vaccines chief Vinay Prasad. Kyle Diamantés is expected to take over as acting commissioner and will testify in place of Makary at an upcoming Capitol Hill hearing.
Why It Matters
The FDA plays a crucial role in regulating drugs, vaccines, and tobacco, impacting a significant portion of consumer spending in the U.S. Makary’s resignation highlights ongoing tensions within the FDA regarding public health policies, including controversial topics such as vaping and abortion medication. His tenure faced scrutiny from both conservative and liberal factions, reflecting the polarized environment surrounding health regulations in the U.S. The agency’s decisions can have wide-ranging effects on public health and safety, making leadership stability essential for effective governance.
Want More Context? 🔎
